Q-omics provides the consensus-scored TMEM177 profile across patient tissues and cancer cell-line models. TMEM177 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TMEM177 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMEM177 RNA expression shows 20,124 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, HNSC, and LSCC as cancer lineages where TMEM177 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM177 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM177 survival associations across molecular data types. TMEM177 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM177 RNA expression–survival associations across cancer types. High TMEM177 expression shows unfavorable associations in LUAD, HNSC, ACC, KIRP and SKCM, but favorable associations in READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TMEM177 RNA expression.
This table summarizes TMEM177 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM177. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM177 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LUAD, LUSC and BLCA. The HNSC box plot shows higher TMEM177 RNA expression in tumor versus normal tissue (log2 FC = +1.090, t-test p < 0.001).
This table shows molecular features associated with TMEM177 in patient tissues and cancer cell lines. In patient samples, TMEM177 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM177 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
